A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
NCT07403968
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
Zasocitinib
Sponsor
Takeda